Advanced

Can sulphonylurea addition to lifestyle changes help to delay diabetes development in subjects with impaired fasting glucose? The Nepi ANtidiabetes StudY (NANSY)

Lindblad, U.; Lindberg, Gunnar LU ; Månsson, Nils-Ove LU ; Ranstam, Jonas LU ; Tyrberg, Maria LU ; Jansson, S.; Lindwall, K.; Svärdh, Mona LU ; Kindmalm, L. and Melander, Arne LU (2011) In Diabetes, Obesity and Metabolism 13(2). p.185-188
Abstract
The Nepi ANtidiabetes StudY (NANSY) is a 5-year randomized, double-blind, placebo-controlled trial in Swedish primary care, examining whether the development of type 2 diabetes (T2D) and retinopathy (separately reported) would be delayed in 40- to 70-year-old subjects with impaired fasting glucose (IFG) who, in addition to lifestyle changes, were treated with either placebo or low-dosage sulphonylurea (SU) (1-mg glimepiride; Amaryl (R)). Of 274 subjects (163 men, 111 women), 138 were allocated to placebo (46.0% men, 56.8% women) and 136 to glimepiride (54.0% men, 43.2% women). The primary endpoint was conversion to diabetes. Average follow-up time was 3.71 years; 96 subjects converted to diabetes, 55 allocated to placebo and 41 to... (More)
The Nepi ANtidiabetes StudY (NANSY) is a 5-year randomized, double-blind, placebo-controlled trial in Swedish primary care, examining whether the development of type 2 diabetes (T2D) and retinopathy (separately reported) would be delayed in 40- to 70-year-old subjects with impaired fasting glucose (IFG) who, in addition to lifestyle changes, were treated with either placebo or low-dosage sulphonylurea (SU) (1-mg glimepiride; Amaryl (R)). Of 274 subjects (163 men, 111 women), 138 were allocated to placebo (46.0% men, 56.8% women) and 136 to glimepiride (54.0% men, 43.2% women). The primary endpoint was conversion to diabetes. Average follow-up time was 3.71 years; 96 subjects converted to diabetes, 55 allocated to placebo and 41 to glimepiride (absolute difference 9.8%; p = 0.072). In conclusion, the study failed to support the notion that low-dose SU added to lifestyle changes in IFG subjects would help to delay the conversion to diabetes. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
IFG, prevention, primary care, randomized trial, sulphonylurea, type 2, diabetes
in
Diabetes, Obesity and Metabolism
volume
13
issue
2
pages
185 - 188
publisher
Wiley-Blackwell
external identifiers
  • wos:000285753700010
  • scopus:78650662421
ISSN
1462-8902
DOI
10.1111/j.1463-1326.2010.01331.x
language
English
LU publication?
yes
id
ff19abea-a238-4878-b292-ccf4c9c990ca (old id 1882637)
date added to LUP
2011-04-01 08:40:32
date last changed
2017-01-01 03:16:03
@article{ff19abea-a238-4878-b292-ccf4c9c990ca,
  abstract     = {The Nepi ANtidiabetes StudY (NANSY) is a 5-year randomized, double-blind, placebo-controlled trial in Swedish primary care, examining whether the development of type 2 diabetes (T2D) and retinopathy (separately reported) would be delayed in 40- to 70-year-old subjects with impaired fasting glucose (IFG) who, in addition to lifestyle changes, were treated with either placebo or low-dosage sulphonylurea (SU) (1-mg glimepiride; Amaryl (R)). Of 274 subjects (163 men, 111 women), 138 were allocated to placebo (46.0% men, 56.8% women) and 136 to glimepiride (54.0% men, 43.2% women). The primary endpoint was conversion to diabetes. Average follow-up time was 3.71 years; 96 subjects converted to diabetes, 55 allocated to placebo and 41 to glimepiride (absolute difference 9.8%; p = 0.072). In conclusion, the study failed to support the notion that low-dose SU added to lifestyle changes in IFG subjects would help to delay the conversion to diabetes.},
  author       = {Lindblad, U. and Lindberg, Gunnar and Månsson, Nils-Ove and Ranstam, Jonas and Tyrberg, Maria and Jansson, S. and Lindwall, K. and Svärdh, Mona and Kindmalm, L. and Melander, Arne},
  issn         = {1462-8902},
  keyword      = {IFG,prevention,primary care,randomized trial,sulphonylurea,type 2,diabetes},
  language     = {eng},
  number       = {2},
  pages        = {185--188},
  publisher    = {Wiley-Blackwell},
  series       = {Diabetes, Obesity and Metabolism},
  title        = {Can sulphonylurea addition to lifestyle changes help to delay diabetes development in subjects with impaired fasting glucose? The Nepi ANtidiabetes StudY (NANSY)},
  url          = {http://dx.doi.org/10.1111/j.1463-1326.2010.01331.x},
  volume       = {13},
  year         = {2011},
}